Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.
Also called NCT07108985
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT07108985
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07108985. Randomized; no masking; primary purpose treatment. Start 2025-09 (anticipated); primary completion 2029-09-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Hyperglycemia
- Condition
- Insulin Resistance
- Intervention (Drug)
- Sitagliptin 100 mg
- Intervention (Drug)
- Sitagliptin 100 mg + Dapagliflozin 10 mg
- Intervention (Drug)
- Sitagliptin 100 mg + Dapagliflozin 10 mg
- Intervention (Drug)
- Sitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg
- Lead sponsor
- Yonsei University
Record details
- Record id
cardio:ct-nct07108985- Content hash
da6a9b45cf8541d0d633ba6d7f45d3493c52629e3b5fef5818b16871d5ebb5a6